BARBITURIC acid was first synthesized by Conrad and Guthzeit in 1882, and in 1903 the 5:5-diethyl derivative was introduced into medicine as a hypnotic by Carl Fischer and von Mering, under the name of Veronal.
In the past, barbituric acid was usually regarded as the cyclic ureide of malonic acid, i.e. as malonyl urea, and its structural formula written in a form which emphasized this relationship. Systematically it is more correct to regard it as a pyrimidine derivative and to write its formula as shown in figure l(a).
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•i\/ been formulated which make it possible to forecast the properties of any new derivative with, some degree of precision. Nevertheless, there arc still some unexplained exceptions. A well known, instance is the compound 5-ethyl, 5-(l, 3-dimethylbutyl) barbituric acid described by Swanson (1934) which in spite of its similarity in structure to pentobarbitone is entirely devoid of hypnotic properties and purely convulsant in action.
The three principal methods for the production of variants are:
(a) substitution of the C s hydrogen atoms by organic radicles, e.g. diethyl barbituric acid. Barbituric acid is one of a group of compounds capable of existing in two forms, the " ketonic " and the " enolic ". The structure shown in figure l(a) does not account for its acidic properties, and the salts formed with the alkali metals are regarded as being derived from the enolic tautomer ( fig. l(b) ) by replacement of one of the hydroxyl hydrogen atoms.
The barbiturates have provided a very fertile field for attempts to correlate chemical structure with pharmacological activity. The number of possible derivatives is practically limitless and very many have been prepared and submitted to investigation. As a result, certain principles have (b) substitution of the N 1 hydrogen by an alkyl radical, e.g. methylphenobarbitone. FIG. 4 Most of the earlier componds resulted from substitution at C 5 . Barbituric acid itself, and its mono-alkyl derivatives are without measurable hypnotic activity. When both C 6 hydrogen atoms are substituted by alkyl groups, activity appears when the total number of carbon atoms in the substituent groups reaches four. A peak is reached at seven OT eight, after which activity tends to decline with further increases. Bromination of one of the substituent alkyl groups enhances activity. Compounds with branched chain substituents usually show greater activity and longer duration of action than the isomeric straight chain compounds. Substitution at C 5 by two aromatic groups yields inactive compounds, but providing that one of the substituents is an open chain group the other may be cyclic. Substitution at N 1 by methyl results in increased activity and shortened duration of action. Enhanced anticonvulsant properties have also been claimed. Higher alkyl groups exert the opposite effect and produce convulsant compounds.
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Replacement of the C 2 oxygen by sulphur to form thiobafbiturates increases solubility in lipids and results in compounds characterized by an extremely short duration of action.
Barbituric acid and its derivatives are weak acids insoluble in water but form water soluble salts with the alkali metals. Solutions of the sodium salts are highly alkaline and decompose on keeping. Both the free acids and sodium salts may be used for oral medication, but only the latter are suitable for intravenous injection. The thiobarbiturates, in the form of their sodium salts, find their principal use as intravenous anaesthetics. They are not suitable for oral administration because of their rather erratic absorption from the gastro-intestinal tract..
The study of structure-activity relationships, •has resulted in the production of a very large number of compounds ranging in activity from barbitone with an average hypnotic dose of 0.5 g to pentobarbitone for which the corresponding dose is 0.1 g. Duration of effect ranges from 12 hours or more in the case of phenobarbitone to approximately 15 minutes for thiopentone. Tatum (1939) classified the barbiturates into long, medium, short and ultra short acting. The long acting group exert their effect over 8 to 12 hours and upwards, the medium acting over 6 to 8 hours, the short acting over 2 to 3 hours, and the ultra short acting over 15 minutes. Duration of activity is a property which is not subject to precise determination, but a classification on this basis serves as a rough guide for clinical purposes.
In tables I and II, the chemical structure of the more important compounds is illustrated, and their duration of activity noted. Many of them are available both as the free acid and the sodium salt, and this leads to some confusion in nomenclature. For instance, in Britain, thiopentone sodium is sold under the proprietary name of Pentothal, whilst in the U.S.A. it is known as Pentothal Sodium. The American usage avoids ambiguity and in the tables the word " sodium " has been added to the proprietary names of compounds which are sodium salts. An exception occurs in the case of Medinal which is the sodium salt of Veronal.
In naming the compounds the official nonproprietary names are printed in capitals, but apart from this, proprietary and non-proprietary names have not been distinguished. The term " official non-proprietary name " denotes the name used to distinguish the compound in the British Pharmacopeia 1953 (B.P.) 
